Harnessing Host Defense Responses To Fight Cancer
Manhattan BioSolutions is an emerging biotech company focused on the discovery of novel precision biologics that harness the power of microbial recognition and host-defense pathways for the treatment of advanced, metastatic cancers. We develop innovative tumor-targeted agents that selectively destroy cancer cells while sparing healthy tissues
Scientific Platforms
Degrader Nucleases
Developing a new generation of human nuclease therapeutics with potent anti-cancer activities. The RNA degrador platform utilizes engineered derivative of naturally occurring enzyme involved in host defense to selectively degrade RNA in tumors
ADCs
Developing novel biologics, Antibody-Drug Conjugates (ADCs) that target cell-surface receptors overexpressed in tumors. The ADCs are designed to selectively eliminate cancer cells via multiple immune-mediated or direct anti-tumor mechanisms
In the News
